Establishing Scrutiny and Reporting Requirements in the Drug Development Life Cycle: Research, Sales, Pricing, and Patient Data Security
Ahmed Al-Mansouri
Department of Computer Science, King Saud University, Saudi Arabia
Layla El-Sayed
Department of Computer Science, American University of Beirut, Lebanon
Abstract
The The drug development life cycle is a multifaceted process involving extensive scrutiny and reporting requirements at various stages, including research, sales, pricing, and patient data security. Regulatory bodies worldwide enforce these requirements to ensure drug safety, efficacy, and ethical marketing practices. In the research phase, stringent guidelines govern clinical trials and data collection to maintain scientific integrity and protect human subjects. During the sales phase, pharmaceutical companies must adhere to transparent reporting of sales data and marketing practices to prevent misleading information and ensure fair competition. Pricing scrutiny involves regulatory oversight to prevent price gouging and ensure drugs are affordable and accessible to the public. Finally, patient data security is paramount, with strict regulations in place to protect sensitive health information from breaches and misuse. This paper provides an in-depth analysis of these scrutiny and reporting requirements, highlighting their importance in maintaining public trust and safeguarding public health. Through a comprehensive review of existing regulations and case studies, we aim to elucidate the critical aspects of each stage in the drug development life cycle and propose best practices for compliance and ethical conduct.
Author Biographies
Ahmed Al-Mansouri, Department of Computer Science, King Saud University, Saudi Arabia
Ahmed Al-Mansouri
Department of Computer Science, King Saud University, Saudi Arabia
Layla El-Sayed, Department of Computer Science, American University of Beirut, Lebanon
Layla El-Sayed
Department of Computer Science, American University of Beirut, Lebanon
